Gateway Wealth Partners LLC Makes New Investment in United Therapeutics Corporation $UTHR

Gateway Wealth Partners LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,404 shares of the biotechnology company’s stock, valued at approximately $1,426,000.

A number of other large investors have also recently made changes to their positions in UTHR. Avoro Capital Advisors LLC increased its stake in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the period. Wellington Management Group LLP lifted its holdings in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC boosted its position in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the period. Janus Henderson Group PLC boosted its position in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after buying an additional 341,383 shares during the period. Finally, Norges Bank bought a new position in United Therapeutics in the 4th quarter worth about $293,418,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $523.63 on Wednesday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market cap of $22.23 billion, a P/E ratio of 19.33, a P/E/G ratio of 1.77 and a beta of 0.58. The firm has a 50-day simple moving average of $546.23 and a 200-day simple moving average of $532.01.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.63 earnings per share. On average, research analysts predict that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on UTHR shares. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $648.33.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,921,276.08. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 512,833 shares of company stock valued at $285,561,257 over the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.